...
首页> 外文期刊>EJNMMI Research >Feasibility of preoperative 125I seed-guided tumoural tracer injection using freehand SPECT for sentinel lymph node mapping in non-palpable breast cancer
【24h】

Feasibility of preoperative 125I seed-guided tumoural tracer injection using freehand SPECT for sentinel lymph node mapping in non-palpable breast cancer

机译:徒手SPECT术前125I种子导向的肿瘤示踪剂注射在不可触及的乳腺癌中进行前哨淋巴结定位的可行性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background This study was designed to explore the feasibility of replacing the conventional peri-/intratumoural ultrasound (US)-guided technetium-99m albumin nanocolloid (99mTc-nanocolloid) administration by an injection of the same tracer guided by a freehand single-photon emission computed tomography (SPECT) device in patients with non-palpable breast cancer with an iodine-125 (125I) seed as tumour marker, who are scheduled for a sentinel lymph node biopsy (SLNB). This approach aimed to decrease the workload of the radiology department, avoiding a second US-guided procedure. Methods In ten patients, the implanted 125I seed was primarily localised using freehand SPECT and subsequently verified by conventional US in order to inject the 99mTc-nanocolloid. The following 34 patients were injected using only freehand SPECT localisation. In these patients, additional SPECT/CT was acquired to measure the distance between the 99mTc-nanocolloid injection depot and the 125I seed. In retrospect, a group of 21 patients with US-guided 99mTc-nanocolloid administrations was included as a control group. Results The depth difference measured by US and freehand SPECT in ten patients was 1.6?±?1.6 mm. In the following 36 125I seeds (34 patients), the average difference between the 125I seed and the centre of the 99mTc-nanocolloid injection depot was 10.9?±?6.8 mm. In the retrospective study, the average distance between the 125I seed and the centre of the 99mTc-nanocolloid injection depot as measured in SPECT/CT was 9.7?±?6.5 mm and was not significantly different compared to the freehand SPECT-guided group (two-sample Student's t test, p?=?0.52). Conclusion We conclude that using freehand SPECT for 99mTc-nanocolloid administration in patients with non-palpable breast cancer with previously implanted 125I seed is feasible. This technique may improve daily clinical logistics, reducing the workload of the radiology department.
机译:背景技术本研究旨在探讨通过注射由手绘单光子发射引导的同一示踪剂来替代常规的肿瘤周围/瘤内超声(美国)引导的tech- 99m白蛋白纳米胶体(99mTc-纳米胶体)给药的可行性。 X线断层扫描(SPECT)装置用于以碘125(125I)种子作为肿瘤标记物的非触诊乳腺癌患者,计划进行前哨淋巴结活检(SLNB)。这种方法旨在减少放射科的工作量,避免了第二次美国指导的程序。方法在10例患者中,首先使用徒手SPECT对植入的125I种子进行局部定位,然后通过常规US验证以注入99mTc-纳米胶体。仅使用徒手SPECT定位注射了以下34位患者。在这些患者中,需要额外的SPECT / CT来测量99mTc-纳米胶体注射液储库与125I种子之间的距离。回顾过去,将21例接受US指导的99mTc-纳米胶体给药的患者作为对照组。结果10例患者通过US和徒手SPECT测量的深度差为1.6±±1.6 mm。在随后的36颗125I种子(34例患者)中,125I种子与99mTc-纳米胶体注射液中心的平均差为10.9?±?6.8 mm。在回顾性研究中,在SPECT / CT中测得的125I种子与99mTc-纳米胶体注射液中心之间的平均距离为9.7?±?6.5 mm,与徒手SPECT引导组相比无显着差异(两个-样本学生t检验,p?=?0.52)。结论我们得出结论,对于先前植入了125I种子的不可触及的乳腺癌患者,使用徒手SPECT进行99mTc-纳米胶体给药是可行的。该技术可以改善日常临床后勤工作,减少放射科的工作量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号